Very Early Nimodipine Use in Stroke "VENUS"

Terminated

Phase 3 Results

Trial Description

To prospectively study the effects of nimodipine administered early after stroke onset.

Interventions

  • Nimodipine (NimotopĀ®)Drug
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Randomized. double-blind, placebo-controlled trial of 454 patients.

Patient Involvement

Patients were randomized to receive nimodipine 30 mg qid, po for 10 days or placebo.

Outcomes

Type Measure Time Frame Safety Issue
Primary All-cause mortality or dependency in daily life (Modified Rankin Scale score >3.11 ) 3 months after inclusion.
Secondary Neurological status and blood pressure 24 hours after inclusion, mortality after 10 days, and adverse events.

Sponsors

Dutch Prevention Fund. Medication supplied by Bayer AG.